Navigation Links
GenVec Reports Fourth Quarter And 2012 Year-End Financial Results
Date:3/22/2013

2013 GuidanceGenVec's Senior Vice President and Chief Financial Officer, Douglas J. Swirsky , commented, "For 2013, we anticipate our cash burn will be between $8.0 million and $9.0 million."

Conference Call InformationGenVec will hold a conference call today at 10:00 a.m. EDT to discuss the Company's financial results and 2013 business outlook.  To listen to the live conference call, please dial 877-558-0567 (U.S. or Canada) or 706-643-4980 (international) and use the following Conference ID: 17801867.  An audio replay of the conference call will be available starting at 1:00 p.m. EDT on March 22, 2013 through March 29, 2013.  To listen to the audio replay, dial 855-859-2056 or 404-537-3406 (international) and use access code 17801867.

A live webcast of the conference call will be available on the Company's website and will be archived for 30 days.  To access the webcast or the replay, go to www.genvec.com, and click on "Investors and Media".

About GenVecGenVec is a biopharmaceutical company using differentiated, proprietary technologies to create superior therapeutics and vaccines. A key component of our strategy is to develop and commercialize our product candidates through collaborations. GenVec is working with leading companies and organizations such as Novartis, Merial, and the U.S. Government to support a portfolio of product programs that address the prevention and treatment of a number of significant human and animal health concerns. GenVec's development programs address therapeutic areas such as hearing loss and balance disorders; as well as vaccines against infectious diseases including respiratory syncytial virus (RSV), herpes simplex virus (HSV), dengue fever, malaria, and human immunodeficiency virus (HIV). In the area of animal health we are developing vaccines against foot-and-mouth disease (FMD). Addit
'/>"/>

SOURCE GenVec, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. GenVec To Release First Quarter 2012 Financial Results And Conduct A Conference Call On May 10, 2012
2. GenVec Appoints Cynthia Collins as President and CEO
3. GenVec Reports Inducement Award
4. GenVec Announces Conditional Approval of FMD Vaccine for Cattle
5. GenVec to Release Second Quarter 2012 Financial Results and Conduct a Conference Call on August 9, 2012
6. GenVec Reports Second Quarter 2012 Financial Results
7. GenVec Reports Third Quarter 2012 Financial Results
8. GenVec to Present at 25th Annual ROTH Conference
9. GenVec To Release Fourth Quarter And Year-end 2012 Financial Results And Conduct A Conference Call On March 22, 2013
10. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
11. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... N.Y. , July 24, 2014  Kinex Pharmaceuticals ... FDA for the Company,s KX2-391 Ointment for the commencement ... This is the Company,s third IND to be allowed ... KX2-391 is a synthetic, orally active and ... tubulin polymerization. KX2-391 promotes the induction of p53, G2/M ...
(Date:7/24/2014)... , July 24, 2014 Consolidated Net ... Business Highlights   , India Business grew ... by 9.33% to Rs. 4,886.70 Mn Rest of World ... Europe Formulations Business grew by 34.53% to Rs. 977.26 Mn ... , Glenmark Pharmaceuticals Limited, the research-led global ...
(Date:7/24/2014)... Boston Children,s Hospital,s Global Pediatric Summit + Awards, ... Tank" – a forum designed to give pediatric health ... product solution to a panel of acclaimed judges for ... the innovation and bring it to market. ... will be moderated by Daymond John of ...
Breaking Medicine Technology:Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA) 2Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA) 3Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA) 4Glenmark's Consolidated Revenue Increases by 20.08% to Rs. 14,869.40 Mn for Q1 FY 14 - 15 2Glenmark's Consolidated Revenue Increases by 20.08% to Rs. 14,869.40 Mn for Q1 FY 14 - 15 3Glenmark's Consolidated Revenue Increases by 20.08% to Rs. 14,869.40 Mn for Q1 FY 14 - 15 4Taking on Tomorrow to Feature "Innovation Tank" Pitch Opportunity for Aspiring Pediatric Health Care Entrepreneurs 2Taking on Tomorrow to Feature "Innovation Tank" Pitch Opportunity for Aspiring Pediatric Health Care Entrepreneurs 3
... MOUNTAIN VIEW, Calif., Nov. 7, 2011 Alexza Pharmaceuticals, ... results for the fiscal quarter ended September 30, 2011 ... the quarters ended September 30, 2011 and 2010, as ... the United States (GAAP), were $13.4 million and $0.6 ...
... LIBERTY, Mo. and DANBURY, Conn., Nov. 7, 2011 ... "Planet"), a privately held specialty pharmaceutical company focused on ... that it had completed an asset sale of ALLERGY ... ACQUISITION LLC, a New Jersey limited liability company. ...
Cached Medicine Technology:Alexza Reports 2011 Third Quarter Financial Results and Provides Business Update 2Alexza Reports 2011 Third Quarter Financial Results and Provides Business Update 3Alexza Reports 2011 Third Quarter Financial Results and Provides Business Update 4Alexza Reports 2011 Third Quarter Financial Results and Provides Business Update 5Alexza Reports 2011 Third Quarter Financial Results and Provides Business Update 6Alexza Reports 2011 Third Quarter Financial Results and Provides Business Update 7
(Date:7/24/2014)... 2014 National Analysts Worldwide, the Philadelphia-headquartered ... will operate globally under the name, NAXION , ... Employee Stock Ownership Plan (ESOP) organization led by majority ... . The firm guides market strategy in target ... , Said McDonald, “We wanted our name to better ...
(Date:7/24/2014)... The report, “Feed Palatability Enhancers & ... (Swine, Poultry, Cattle, Pets, Aquaculture, and Others) - Global ... feed palatability enhancers & modifiers market with an analysis ... value, of types of feed flavors, sweeteners, and text ... figures spread through 275 pages and in-depth TOC on ...
(Date:7/24/2014)... and faster, according to a new study published in ... to tackle melanoma, the most deadly form of skin ... of Manchester found that some melanoma cells are particularly ... surrounding tissue, while other melanoma cells are the opposite ... tumour, the faster growing cells ,piggy-back, along with the ...
(Date:7/24/2014)... The Biofeedback Federation of ... distribution agreement with game development company Zukor Interactive. ... groups to offer Zukor's Grind , a ... neurofeedback in European and international markets. , Zukor's ... to be used as a biofeedback/neurofeedback training tool. ...
(Date:7/24/2014)... WEDNESDAY, July 23, 2014 (HealthDay News) -- Even though its ... best known as Tylenol -- does not help treat lower ... The researchers found the drug was no more effective than ... acute lower back pain. Besides showing no effect in ... help in improving sleep woes tied to back pain, nor ...
Breaking Medicine News(10 mins):Health News:National Analysts Worldwide Announces a Change of Name to NAXION 2Health News:National Analysts Worldwide Announces a Change of Name to NAXION 3Health News:Feed Palatability Enhancers & Modifiers Market Worth $3172.6 Million by 2019 - Report by MarketsandMarkets 2Health News:Feed Palatability Enhancers & Modifiers Market Worth $3172.6 Million by 2019 - Report by MarketsandMarkets 3Health News:Feed Palatability Enhancers & Modifiers Market Worth $3172.6 Million by 2019 - Report by MarketsandMarkets 4Health News:Piggy-backing cells hold clue to skin cancer growth 2Health News:Biofeedback Federation of Europe Enters Distribution Agreement with Zukor Interactive 2Health News:Biofeedback Federation of Europe Enters Distribution Agreement with Zukor Interactive 3Health News:Acetaminophen May Not Help Against Back Pain, Study Contends 2Health News:Acetaminophen May Not Help Against Back Pain, Study Contends 3
... ... year’s edition of The Leading Physicians of the World. With a long track record of ... of the World wanted to honor the specialty so integral to the surgical team; anesthesiology. ... (PRWEB) June 26, 2010 ...
... ... by whiplash injury should be made aware of their legal entitlement to file a whiplash ... ... leading whiplash injury claims lawyers, is today warning of the need for greater awareness of ...
... ... Haitian children, mostly refugees and orphans who go all day without eating. Shelene Bryan and ... ... and her Skip1 team of volunteers were deep inside Haiti and the Dominican Republic delivering ...
... ... a renewable resource. , ... June 26, 2010 -- Laser and copier toners use over 146,000,000 gallons of oil per ... or Forestry products, therefore, eliminating the need for petroleum products. The term bio-product is ...
... studying and treating disease and for the practice of ... the cells that may one day be transplanted into ... studies going on worldwide, scientists at the UCLA Broad ... X chromosome inactivation take place in very early passages ...
... By Maryann Mott HealthDay Reporter , FRIDAY, June ... chuckle out of watching their dog sleep while its paws race ... in dreamland, and scientists say they were right: Pets do ... of past events replay in their minds much the same way ...
Cached Medicine News:Health News:The International Association of Anesthesiologists Places its Top Doctors in the Renowned Medical Publication, The Leading Physicians of the World. 2Health News:The International Association of Anesthesiologists Places its Top Doctors in the Renowned Medical Publication, The Leading Physicians of the World. 3Health News:Whiplash Claims Warns on Awareness of Personal Injury Compensation Entitlement 2Health News:Shelene Bryan and Skip1.org Help Build Kitchen for Haitian Orphans 2Health News:Great Office Buys Announces the Addition of Elite Brand Bio-Based Toners to their Product Line 2Health News:Chromosomal variations found in early passage female embryonic stem cells 2Health News:Chromosomal variations found in early passage female embryonic stem cells 3Health News:Where Do Pets Go When They Dream? 2Health News:Where Do Pets Go When They Dream? 3
... heavy duty, controlled stretch knee support that ... allowing full range of motion. The ... the knee, and help to keep the ... This is an excellent support for ...
... breathable foam. Three piece design for precise ... loop closures. Lightweight rigid posterior stays with ... with optional hot and cold therapy Gel ... pain cycle by providing cold therapy to ...
... Scoring: , One of the outstanding features ... our patented Three-Dimensional Molding Technology. , This ... brace which effectively controls the bunching and ... comfort to the wearer. , ...
... new padding system from Innovation Sports. Exceptionally ... contours to the unique anatomy of each ... Gel Fit's proprietary Octogrip™ Anti-Slip System improves ... when the brace is strapped on. Gel ...
Medicine Products: